These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24602376)

  • 21. Postmarket policy considerations for biosimilar oncology drugs.
    Renwick MJ; Smolina K; Gladstone EJ; Weymann D; Morgan SG
    Lancet Oncol; 2016 Jan; 17(1):e31-8. PubMed ID: 26758759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biosimilars Ready, At Last, To Make Their Entrance: Stars Are Born or Do They Fizzle?
    Reinke T
    Manag Care; 2017 Mar; 26(3):20-23. PubMed ID: 28510515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Biosimilars].
    Krämer I
    Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.
    Vandenplas Y; Simoens S; Van Wilder P; Vulto AG; Huys I
    Front Pharmacol; 2021; 12():644187. PubMed ID: 33953678
    [No Abstract]   [Full Text] [Related]  

  • 25. Biosimilar competition: Early learning.
    Frank RG; Shahzad M; Kesselheim AS; Feldman W
    Health Econ; 2022 Apr; 31(4):647-663. PubMed ID: 35023225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of generic substitution on price competition in Finland.
    Aalto-Setälä V
    Eur J Health Econ; 2008 May; 9(2):185-91. PubMed ID: 17508226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009-2019.
    García-Goñi M; Río-Álvarez I; Carcedo D; Villacampa A
    Pharmaceuticals (Basel); 2021 Apr; 14(4):. PubMed ID: 33918795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Do follow-on therapeutic substitutes induce price competition between hospital medicines? Evidence from the Danish hospital sector.
    Hostenkamp G
    Health Policy; 2013 Jun; 111(1):68-77. PubMed ID: 23587548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Shaping Pharmaceutical Tenders for Effectiveness and Sustainability in Countries with Expanding Healthcare Coverage.
    Maniadakis N; Holtorf AP; Otávio Corrêa J; Gialama F; Wijaya K
    Appl Health Econ Health Policy; 2018 Oct; 16(5):591-607. PubMed ID: 29987759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incentives for market penetration of biosimilars in Belgium and in five European countries.
    Swartenbroekx N; Farfan-Portet ; Espín J; Gerkens S
    J Pharm Belg; 2014 Dec; (4):36-46. PubMed ID: 25562926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug prices in Latin American countries: the case of rheumatoid arthritis Biosimilars.
    Mosegui GBG; Antõnanzas F; de Mello Vianna CM; Rojas P
    Adv Rheumatol; 2021 Feb; 61(1):14. PubMed ID: 33632333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison between biosimilar filgrastim vs other granulocyte-colony stimulating factor formulations (originator filgrastim, peg-filgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network.
    Marchesi F; Cerchiara E; Dessanti ML; Gumenyuk S; Franceschini L; Palombi F; Pisani F; Romano A; Spadea A; Pupo L; Annibali O; La Malfa A; Arcese W; Mengarelli A
    Br J Haematol; 2015 Apr; 169(2):293-6. PubMed ID: 25371286
    [No Abstract]   [Full Text] [Related]  

  • 33. First monoclonal antibody biosimilars: tackling the challenge of substitution.
    Bocquet F; Paubel P
    J Med Econ; 2016 Jun; 19(6):645-7. PubMed ID: 27080815
    [No Abstract]   [Full Text] [Related]  

  • 34. Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis.
    Barcina Lacosta T; Vulto AG; Huys I; Simoens S
    Front Pharmacol; 2022; 13():1031910. PubMed ID: 36588696
    [No Abstract]   [Full Text] [Related]  

  • 35. A concept for multi-winner tenders for medicinal products with balancing between efficient prices, long-term competition and sustainability of supply.
    Németh G; Mágó ML; Kaló Z; Lám J; Balogh T; Brodszky V
    Front Med (Lausanne); 2023; 10():1282698. PubMed ID: 37964880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries.
    Abraham I; Han L; Sun D; MacDonald K; Aapro M
    Future Oncol; 2014; 10(9):1599-609. PubMed ID: 25145430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition.
    San-Juan-Rodriguez A; Gellad WF; Good CB; Hernandez I
    JAMA Netw Open; 2019 Dec; 2(12):e1917379. PubMed ID: 31834391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Big cost savings from small filgrastim unit doses.
    Sinsabaugh DK; Freyer DR
    Am J Hosp Pharm; 1993 Jul; 50(7):1363-4. PubMed ID: 7689787
    [No Abstract]   [Full Text] [Related]  

  • 39. Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in Germany.
    Blankart KE; Arndt F
    Int J Environ Res Public Health; 2020 Jun; 17(11):. PubMed ID: 32526943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Switching Between Epoetins: A Practice in Support of Biosimilar Use.
    D'Amore C; Da Cas R; Rossi M; Traversa G
    BioDrugs; 2016 Feb; 30(1):27-32. PubMed ID: 26728875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.